Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial

Immunobiology

Volumn 222, Issue 2, 2017, Pages 164-168

  Shi, Guoxun ^a   Hua, Minhui ^a   Xu, Qiangwei ^a   Ren, Tianli ^a  

^a WUXI NO 2 PEOPLE S HOSPITAL   (China)

Author keywords

C reactive protein; Erythrocyte sedimentation rate; Resveratrol; Takayasu arteritis; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; PLACEBO; RESVERATROL; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ACUTE DISEASE; ADULT; AORTA ARCH SYNDROME; ARTICLE; BIRMINGHAM VASCULAR ACTIVITY SCORE; C REACTIVE PROTEIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR BLOOD LEVEL; ADOLESCENT; ANTAGONISTS AND INHIBITORS; AORTIC ARCH SYNDROME; BLOOD; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; STILBENES; TAKAYASU ARTERITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85002766838     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2016.10.008     Document Type: Article

References (34)

1. Arend, W.P., Michel, B.A., Bloch, D.A., Hunder, G.G., Calabrese, L.H., Edworthy, S.M., Fauci, A.S., Leavitt, R.Y., Lie, J.T., Lightfoot, R.W. Jr., et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum., 33, 1990, 1129.
2. Babu, D., Leclercq, G., Goossens, V., Remijsen, Q., Vandenabeele, P., Motterlini, R., Lefebvre, R.A., Antioxidant potential of CORM-A1 and resveratrol during TNF-alpha/cycloheximide-induced oxidative stress and apoptosis in murine intestinal epithelial MODE-K cells. Toxicol. Appl. Pharmacol., 288, 2015, 161.
3. Buonuomo, P.S., Bracaglia, C., Campana, A., Insalaco, A., Pardeo, M., Cortis, E., Ugazio, A.G., Infliximab therapy in pediatric Takayasu's arteritis: report of two cases. Rheumatol. Int., 31, 2011, 93.
4. Cheng, X., Wang, Q., Li, N., Zhao, H., Effects of resveratrol on hippocampal astrocytes and expression of TNF-alpha in Alzheimer's disease model rate. Wei Sheng Yan Jiu, 44, 2015, 610.
5. Comarmond, C., Plaisier, E., Dahan, K., Mirault, T., Emmerich, J., Amoura, Z., Cacoub, P., Saadoun, D., Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun. Rev., 11, 2012, 678.
6. Hoffman, G.S., Merkel, P.A., Brasington, R.D., Lenschow, D.J., Liang, P., Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum., 50, 2004, 2296.
7. Ishihara, T., Haraguchi, G., Tezuka, D., Kamiishi, T., Inagaki, H., Isobe, M., Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ. J., 77, 2013, 477.
8. Liu, X.J., Bao, H.R., Zeng, X.L., Wei, J.M., Effects of resveratrol and genistein on nuclear factorkappaB, tumor necrosis factoralpha and matrix metalloproteinase9 in patients with chronic obstructive pulmonary disease. Mol. Med. Rep., 13, 2016, 4266.
9. Luqmani, R.A., Bacon, P.A., Moots, R.J., Janssen, B.A., Pall, A., Emery, P., Savage, C., Adu, D., Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM, 87, 1994, 671.
10. Macedo, R.C., Vieira, A., Marin, D.P., Otton, R., Effects of chronic resveratrol supplementation in military firefighters undergo a physical fitness test-a placebo-controlled, double blind study. Chem. Biol. Interact., 227, 2015, 89.
11. Maffei, S., Di Renzo, M., Santoro, S., Puccetti, L., Pasqui, A.L., Refractory Takayasu arteritis successfully treated with infliximab. Eur. Rev. Med. Pharmacol. Sci., 13, 2009, 63.
12. Maksimowicz-McKinnon, K., Hoffman, G.S., Takayasu arteritis: what is the long-term prognosis?. Rheum. Dis. Clin. North Am., 33, 2007, 777.
13. Maksimowicz-McKinnon, K., Clark, T.M., Hoffman, G.S., Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum., 56, 2007, 1000.
14. Minciullo, P.L., Catalano, A., Mandraffino, G., Casciaro, M., Crucitti, A., Maltese, G., Morabito, N., Lasco, A., Gangemi, S., Basile, G., Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity. Arch. Immunol. Ther. Exp. (Warsz), 64, 2016, 111.
15. Molloy, E.S., Langford, C.A., Clark, T.M., Gota, C.E., Hoffman, G.S., Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann. Rheum. Dis., 67, 2008, 1567.
16. Mukherjee, S., Dudley, J.I., Das, D.K., Dose-dependency of resveratrol in providing health benefits. Dose Response, 8, 2010, 478.
17. Nasu, T., Takayasu's truncoarteritis in Japan. A statistical observation of 76 autopsy cases. Pathol. Microbiol. (Basel), 43, 1975, 140.
18. Neves, H., Kwok, H.F., Recent advances in the field of anti-cancer immunotherapy. BBA Clin., 3, 2015, 280.
19. Nooshin, D., Neda, P., Shahdokht, S., Ali, J., Ten-year investigation of clinical, laboratory and radiologic manifestations and complications in patients with Takayasu's arteritis in three university hospitals. Malays. J. Med. Sci., 20, 2013, 44.
20. Nunes, G., Neves, F.S., Melo, F.M., de Castro, G.R., Zimmermann, A.F., Pereira, I.A., Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev. Bras. Reumatol., 50, 2010, 291.
21. Pan, W., Yu, H., Huang, S., Zhu, P., Resveratrol protects against TNF-alpha-induced injury in human umbilical endothelial cells through promoting sirtuin-1-induced repression of NF-KB and p38 MAPK. PLoS One, 11, 2016, e0147034.
22. Parameshwarappa, S. Kallappa, Mandjiny, N., Rajagopalan, B. Kavumkal, Radhakrishnan, N., Samavedam, S., Unnikrishnan, M., Intact giant abdominal aortic aneurysm due to Takayasu arteritis. Ann. Vasc. Surg., 27(671), 2013, e11.
23. Park, M.C., Lee, S.W., Park, Y.B., Lee, S.K., Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford), 45, 2006, 545.
24. Quartuccio, L., Schiavon, F., Zuliani, F., Carraro, V., Catarsi, E., Tavoni, A.G., Bombardieri, S., Punzi, L., De Vita, S., Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin. Exp. Rheumatol., 30, 2012, 922.
25. Samsami-Kor, M., Daryani, N.E., Asl, P.R., Hekmatdoost, A., Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-Blind, placebo-controlled pilot study. Arch. Med. Res., 46, 2015, 280.
26. Schmidt, J., Kermani, T.A., Bacani, A.K., Crowson, C.S., Matteson, E.L., Warrington, K.J., Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res. (Hoboken), 64, 2012, 1079.
27. Tanaka, F., Kawakami, A., Iwanaga, N., Tamai, M., Izumi, Y., Aratake, K., Arima, K., Kamachi, M., Nakamura, H., Huang, M., Ida, H., Origuchi, T., Eguchi, K., Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern. Med., 45, 2006, 313.
28. Tato, F., Rieger, J., Hoffmann, U., Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int. Angiol., 24, 2005, 304.
29. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M.J., Garcia-Almagro, F.J., Ruiz-Ros, J.A., Garcia-Conesa, M.T., Tomas-Barberan, F.A., Espin, J.C., One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol., 110, 2012, 356.
30. Tome-Carneiro, J., Larrosa, M., Gonzalez-Sarrias, A., Tomas-Barberan, F.A., Garcia-Conesa, M.T., Espin, J.C., Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des., 19, 2013, 6064.
31. Tome-Carneiro, J., Larrosa, M., Yanez-Gascon, M.J., Davalos, A., Gil-Zamorano, J., Gonzalvez, M., Garcia-Almagro, F.J., Ruiz Ros, J.A., Tomas-Barberan, F.A., Espin, J.C., Garcia-Conesa, M.T., One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res., 72, 2013, 69.
32. Tripathy, N.K., Gupta, P.C., Nityanand, S., High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin. Immunol., 118, 2006, 154.
33. Wallis, R.S., Ehlers, S., Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin. Arthritis Rheum., 34, 2005, 34.
34. Wang, X.H., Zhu, L., Hong, X., Wang, Y.T., Wang, F., Bao, J.P., Xie, X.H., Liu, L., Wu, X.T., Resveratrol attenuated TNF-alpha-induced MMP-3 expression in human nucleus pulposus cells by activating autophagy via AMPK/SIRT1 signaling pathway. Exp. Biol. Med. (Maywood), 2016.